Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19 (ACTIV-6) (2023)

Peer-Reviewed Study · Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, et al. (31 authors) · March 21, 2023

Naggie S et al., 2023-03-21: The ACTIV-6 higher-dose substudy: 1432 outpatients randomized to ivermectin up to 600 micrograms/kg daily for six days or placebo, with no improvement in time to sustained recovery.

treatment with ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo did not improve time to sustained recovery

Naggie S et al., 2023-03-21: The ACTIV-6 higher-dose substudy: 1432 outpatients randomized to ivermectin up to 600 micrograms/kg daily for six days or placebo, with no improvement in time to sustained recovery. Decentralized, double-blind, randomized, placebo-controlled platform trial, N=1432 adults older than 30 with confirmed COVID-19, 93 sites in the United States, February 2022 onward; ivermectin maximum targeted dose 600 micrograms/kg daily for 6 days vs placebo. Composite of death, hospitalization or urgent/emergency care 6.0% vs 6.0% (HR 1.0, 95% CrI 0.6-1.5). Same disclosure pattern as IVE-33 (Naggie: NIH grants plus Gilead and AbbVie). NCT04885530. This is the trial that answers the 'too low a dose' criticism directly, which is why it is recorded here. Study type: randomized trial.